Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
Corvari V, Narhi LO, Spitznagel TM, Afonina N, Cao S, Cash P, Cecchini I, DeFelippis MR, Garidel P, Herre A, Koulov AV, Lubiniecki T, Mahler HC, Mangiagalli P, Nesta D, Perez-Ramirez B, Polozova A, Rossi M, Schmidt R, Simler R, Singh S, Weiskopf A, Wuchner K.
Corvari V, et al. Among authors: cao s.
Biologicals. 2015 Nov;43(6):457-73. doi: 10.1016/j.biologicals.2015.07.011. Epub 2015 Aug 29.
Biologicals. 2015.
PMID: 26324466
Review.